System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Richard M Goldberg

Oncology — West Virginia University, United States

LeadR Profile

Richard M Goldberg West Virginia University United States
2 162 ScienceLeadR Reputation 2162

Unlock

Register Login
Network Map

Oncology

Subspecialties: Gastroenterology - Internal Medicine - Public Health

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Short Biography

Richard M Goldberg, MD retired from academic medicine in December of 2019. He worked as a practicing oncologist, clinical trialist, and cancer center executive at multiple centers including Mayo Clinic, UNC, OSU, and WVU. Now he is engaging with both start-up and well-established pharmaceutical and technology companies on drug and biomarker development, as an expert witness in patent law disputes, and by serving on data safety monitoring boards. He remains the editor for GI cancers for UpToDate, He continues to serve as the Associate Group Chair for the NCI funded oncology cooperative group the Alliance. He is the chair of the Lower GI Committee of the American Joint Commission on Cancer that is revising the AJCC Staging Manual for the 9th edition. He also continues to mentor GI oncologists locally, around the country, and across the world giving early, mid-career, and senior academic physicians and administrative physicians research and career advice. Considered an international leader in gastrointestinal cancer treatment and research as well as in leadership of cancer programs in academic medicine, Dr. Goldberg has been principal investigator, co-PI, co-investigator and mentor on multiple research and training grants funded through the National Cancer Institute (NCI). He has published more than 450 papers in peer-reviewed journals. He led the phase III trial that provided the data that led to the Food and Drug Administration’s licensing of oxaliplatin as indicated for the treatment of metastatic colorectal cancer in collaboration with collaborators from Sanofi. The FOLFOX regimen remains the standard of care in that setting 20 years later. His research focuses on defining new treatments, elucidating inherited cancer susceptibility, development of new technologies and identification of predictive and prognostic factors in GI cancers. Dr. Goldberg is a graduate of Harvard University, earning an undergraduate degree cum laude in biology in 1975 and received his medical degree from the State University of New York Upstate Medical University in 1979 where he was elected to the Alpha Omega Alpha honor medical society. He completed his residency at Emory University and his medical oncology fellowship at Georgetown University. He is a member of the board of directors of Fight Colorectal Cancer, a patient advocacy organization. He has been honored as a Fellow in the American College of Physicians and the American Society of Clinical Oncology.

Organizations

Career arc: 1984 - 2026
Source: PubMed

West Virginia University

could not re-read experiences after save", error); return null; } if (persistedEntries === null) { return null; } if (persistedEntries.length === 0 && sent.some((entry) => entry.isvisible !== false)) { console.warn(" re-read after save came back empty, keeping the edited entries"); return null; } this.state.current.experience = persistedEntries; const expected = this.yearsSignature(sent); const received = this.yearsSignature(persistedEntries.map((entry) => ({ isvisible: entry.isvisible, topresent: entry.topresent, year_start: entry.startperiod, year_stop: entry.endperiod }))); if (expected !== received) { console.error(" saved experiences were not persisted as sent", { sent: expected, received: received }); return false; } return true; }, async fetchExperiences() { const response = await $.ajax({ url: ajaxLoadUserData, type: "POST", data: { security: ajaxDataLoadUserData.security, data_to_load: "OrganizationHisto", } }); const parsedData = JSON.parse(response); if (parsedData.loaded === false || !parsedData.user_data || !Array.isArray(parsedData.user_data)) { return null; } return parsedData.user_data.map((value, index) => ({ company: value["name"], url: "", position: (value.hasOwnProperty("position") ? ( value["position"] ) : ( "" ) ), startperiod: value["year_start"], endperiod: value["year_stop"], topresent: (value.hasOwnProperty("topresent") ? ( value["topresent"] ) : ( false ) ), orgid: value["orgid"], isvisible: (value.hasOwnProperty("isvisible") ? ( value["isvisible"] ) : ( true ) ), description: "", tags: [], isOpen: false, ismain: (value.hasOwnProperty("ismain") ? ( value["ismain"] ) : ( (index === 0) ? true : false ) ) })); }, async loadDataOnMount() { this.loading = true; try { const experiences = await this.fetchExperiences(); this.loadFailed = experiences === null; if (experiences !== null) { this.state.current.experience = experiences; } } catch (error) { console.warn(" could not load experiences", error); this.loadFailed = true; } this.loading = false; } }, computed: { experience: { get() { return this.state.current.experience }, }, }, async mounted() { await this.loadDataOnMount() }, } }; })

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 599

Citations

Citations: 56 196 1st author: 36 Last author: 100 Unique author: 22

Main journals

J Clin Oncol 235
Clin Cancer Res 29
Oncologist 22
Clin Colorectal Cancer 20
J Natl Cancer Inst 20

Best Journals

J Clin Oncol 91
N Engl J Med 6
JAMA 5

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Development of a Computational Histology Artificial Intelligence-Powered Prognostic Biomarker in Colorectal Cancer in The Cancer Genome Atlas.
telepathology, intelligence, neoplasms, pathology, genome, biomarkers, histology, colorectal neoplasms, artificial intelligence		World J Oncol20260
ypTNM versus pTNM staging after neoadjuvant therapy in rectal cancer.
neoplasms, classification, neoadjuvant therapy, rectal neoplasms, therapeutics, prognosis		J Natl Cancer Inst20260
Sex differences in efficacy and toxicity of first-line treatment of metastatic colorectal cancer: An analysis of 18,041 patients in the ARCAD CRC database.
neoplasms, drug therapy, sex characteristics, sex, therapeutics, colorectal neoplasms, chemotherapy, sex differences		Eur J Cancer20260
Clinical and molecular characterization of AXL in colorectal cancer, CALGB (Alliance)/SWOG 80405 and real-world data.
leucovorin, interferon-gamma, cells, tumor necrosis factor-alpha, neoplasms, biomarkers, fluorouracil, immunotherapy, therapeutics, colorectal neoplasms		J Immunother Cancer20250
The Definition of Cure in Colon Cancer: A Pooled Analysis of 15 Randomized Clinical Trials.
incidence, communication, neoplasms, colon, drug therapy, chemotherapy, adjuvant, colonic neoplasms, chemotherapy		JAMA Oncol20250

Clinical Studies 20

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 1 Study Chair: 4

By phase:

Phase 3 9
Phase 2 7
N/A 2
Phase 1 2

By status:

Completed 19
Unknown 1

By type:

Interventional 19
Observational 1

By Monocentric/Multicentric:

monocentric 5
multicentric2to4 1
multicentric5to9 1
multicentricup10 13

Main Topics

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS